Ainos signs non-binding MOU with Taiwan Tanabe for VELDONA manufacturing and Taiwan market

Ainos, Inc.

Non-binding MOU with Taiwan Tanabe Seiyaku (Mitsubishi Tanabe subsidiary) for exclusive marketing, manufacturing, and marketing authorization of VELDONA in Taiwan.
Exclusive right of first negotiation for 3 months from Nov 27, 2024, extendable by 3 months with mutual written notice.
License fees, milestones, and profit-sharing to be agreed in future definitive agreement, contingent on VELDONA NDA approval in Taiwan.
VELDONA is low-dose oral interferon-alpha for Sjögren's syndrome; prior studies showed symptom alleviation and good safety profile.
Ainos believes partnership will accelerate global market entry; Sjögren's syndrome market projected billions in 5 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.